China Leaders Vow To Reduce Drug Prices Even More, Expand Healthcare
This article was originally published in PharmAsia News
China’s National People’s Congress ended its annual meeting with a promise to extend its program of reducing the prices of pharmaceuticals as it continues a reform of the healthcare system.
You may also be interested in...
At its 14-15 September virtual meeting, the Cosmetic Ingredient Review’s Expert Panel issued five final ingredient reports, four tentative reports, and insufficient data announcements for seven ingredients or ingredient groups, including silicates and 60 red algae ingredients.
New proposed rule says a manufacturer’s knowledge of the unapproved use of a product does not alone determine intended use. Former FDA lawyer says rule could set off fireworks over the scope of what the agency considers evidence of off-label use.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.